Randomized phase III study of S-1 alone versus S-1 plus lentinan in advanced or recurrent gastric cancer

Biotherapy

Volumn 21, Issue 5, 2007, Pages 315-321

  Yoshino, Shigefumi ^a   Oka, Masaaki ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gastric cancer; Lentinan; Phase III study; QOL; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; COMPLEMENT COMPONENT C3; LENTINAN;

ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPLEMENT HEMOLYSIS TEST; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; IMMUNOLOGICAL PARAMETERS; JAPAN; MONOTHERAPY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; STOMACH CANCER; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 35348998553     PISSN: 09142223     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Chihara, G., Maeda, Y., Hamuro, J., et al.: Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) Sing. Nature 222: 687-688, 1969.
2. Maeda, Y. Y, and Chihara, G.: The effects of neonatal thymectomy on the antitumor activity of lentinan, carboxymethylpachymaran and zymosan, and their effects on various immune responses. Int. J. Cancer 11: 153-161, 1973.
3. Hamuro, J. and Chihara, G.: Lentinan, a T cell oriented immunopotentiator: its experimental and clinical applications and possible mechanism of immune modulation. In Immunomodulation agents and their mechanisms (edited by Fenichel, R. L. and Chirigos, M. A.), Marcel Dekker Inc., New York and Basel, 1985, pp.409-436.
4. Hamuro, J., Röllinghoff, M. and Wagner, H.: β (1→3) glucan-mediated augmentation of alloreactive murine cytotoxic T-lymphocytes in vivo. Cancer Res. 38: 3080-3085, 1978.
5. Hamuro, J., Röllinghoff, M. and Wagner, H.: Induction of cytotoxic peritoneal exudate cells by T-cell immune adjuvants of the β (1→3) glucan-type lentinan and its analogues. Immunology 39: 551-559, 1980.
6. Japanese source
7. Japanese source
8. Japanese source
9. Japanese source
10. Japanese source
11. BIOTHERAPY 4: 941-948, 1990.
12. BIOTHERAPY 5: 721-733, 1991.
13. Ochiai, T., Isono, K., Suzuki, T., et al.: Effect of immunotherapy with Lentinan on patients' survival and immunological parameters in patients with advanced gastric cancer: Results of a multi-central randomized controlled study. Int. J. Immunotherapy VIII: 161-169, 1992.
14. BIOTHERAPY 7: 1224-1233, 1993.
15. Biotherapy 10: 60-65, 1996.
16. Nakano, H., Namatame, K., Nemoto, H., et al.: A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Hepatogastroenterology 46: 2662-2668, 1999.
17. Oba, K., Morita, S., Matsui, T., et al.: An individual patient data meta-analysis of the immunochemotherapy using lentinan in patients with advanced gastric cancer. Proc. ASCO 25(abstr.): 15136, 2007.
18. Japanese source
19. Japanese source
20. Japanese source
21. Yoshino, S., Tabata, T., Hazama, S., et al.: Immunoregulatory effect of the antitumor polysaccharide lentinan on Th1/Th2 balance in patients with digestive cancers. Anticancer Res. 20: 4707-4712, 2000.
22. Matsuoka, H., Seo, Y., Wakasugi, H., et al.: Lentinan potentiates immunity and prolongs the survival time of some patients. Anticancer Res. 17: 2751-2755, 1997.
23. Japanese source
24. Japanese source
25. Oka, M., Hazama, S., Suzuki, M., et al.: In vitro and in vivo analysis of human leukocyte binding by the antitumor polysaccharide, lentinan. Int. J. Immunopharmacol. 18: 211-216, 1996.
26. Japanese source
27. Japanese source
28. Boku, N., Yamamoto, S., Shirao, K., et al.: Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). Proc. ASCO 25(abstr.): LBA4513, 2007.
29. Narahara, H., Koizumi, W., Hara, T., et al.: Randomized phase III study of S-1 alone versus S-1 + cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial). Proc. ASCO 25 (abstr.): 4514, 2007.
30. Biotherapy 19(Suppl. I): 61, 2005.
31. Sakata, Y., Ohtsu, A., Horikoshi, N., et al.: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur. J. Cancer 34: 1715-1720, 1998.